Skip to main content
logo
Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
10.25
-0.17 (-1.63%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Solid Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----8.0913.62
Revenue Growth
-----40.57%-
Cost of Revenue
----78.4258.74
Gross Profit
-----70.33-45.12
Selling, General & Admin
44.7538.8833.327.7524.0827.14
Research & Development
167.4140.3396.4376.56--
Operating Expenses
212.15179.21129.73104.3224.0827.14
Operating Income
-212.15-179.21-129.73-104.32-94.4-72.25
Interest Expense
---0.34-0.44--
Interest & Investment Income
10.059.99.477.582.620.06
Other Non Operating Income (Expenses)
-5-5.02-4.11.1-0.380
EBT Excluding Unusual Items
-207.1-174.33-124.7-96.08-92.17-72.19
Merger & Restructuring Charges
---0.06-12.05-
Other Unusual Items
----18.24-
Pretax Income
-207.1-174.33-124.7-96.02-85.98-72.19
Earnings From Continuing Operations
-207.1-174.33-124.7-96.02-85.98-72.19
Net Income
-207.1-174.33-124.7-96.02-85.98-72.19
Net Income to Common
-207.1-174.33-124.7-96.02-85.98-72.19
Net Income Growth
------
Shares Outstanding (Basic)
11188412097
Shares Outstanding (Diluted)
11188412097
Shares Change
80.98%114.38%105.27%133.60%19.59%105.58%
EPS (Basic)
-1.87-1.99-3.06-4.83-10.10-10.14
EPS (Diluted)
-1.87-1.99-3.06-4.83-10.10-10.14
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-187.81-157.44-100.67-95.7-100.99-79.05
Free Cash Flow Per Share
-1.70-1.80-2.47-4.81-11.87-11.11
Operating Margin
-----1166.35%-530.50%
Profit Margin
-----1062.28%-530.01%
Free Cash Flow Margin
-----1247.74%-580.36%
EBITDA
-210.52-177.57-127.27-101.73-92-69.29
D&A For EBITDA
1.631.642.462.582.412.96
EBIT
-212.15-179.21-129.73-104.32-94.4-72.25
SEC Filings: 10-K · 10-Q